Ignite Creation Date:
2024-05-06 @ 6:28 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05679908
Status:
COMPLETED
Last Update Posted:
2024-03-07
First Post:
2022-12-19
Brief Title:
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
Sponsor:
Tonix Pharmaceuticals Inc
Organization:
Tonix Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Double-blind Randomized Multicenter Placebo-controlled Three Arm Parallel Study to Evaluate the Efficacy and Safety of TNX-1900 Intranasal Oxytocin in Patients With Chronic Migraine PREVENTION Study
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PREVENTION
Brief Summary:
This is a phase 2 double-blind randomized multicenter placebo-controlled three arm parallel study to evaluate the efficacy and safety of two different dosages 30 IU daily and 60 IU daily of TNX-1900 in patients with chronic migraine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None